{"ATC Code":"C01EB10","Abbreviation":"A","Aliases":["Adenine riboside","β-D-Adenosine","Nucleocardyl","Adenosin","Sandesin","Boniton","Myocol","Adenine nucleoside","Adenocor","β-Adenosine"],"Biological Half-Life":"The half life of adenosine in blood is less than 10 seconds.","CAS":"58-61-7","ChEBI":"CHEBI:16335","ChEMBL":"CHEMBL477","ChemicalClasses":[],"Chirality":"absolute","Color/Form":"Needles (from water +3/2)","Decomposition":"When heated to decomposition, it emits toxic funes of /nitrogen oxides/.","Dosing Info":[],"Drug Indication":"Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy in patients unable to adequately exercise. It is also indicated to convert sinus rhythm of paroxysmal supraventricular tachycardia.","Drug Warnings":"Contraindications include known hypersensitivity to adenosine, second- or third-degree AV block (except in patients with a functioning artificial pacemaker), sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker), and known or suspected bronchoconstrictive or bronchospastic lung disease (eg, asthma).","DrugClasses":[],"EINECS":"200-389-9","European Community (EC) Number":"200-389-9","FDA Pharmacological Classification":"K72T3FS567","HMDB ID":"HMDB0000050","HeavyAtomCount":19,"Human Drugs":"Human drug -\u003e Prescription; None (Tentative Approval); Discontinued; Active ingredient (ADENOSINE)","IUPACName":"(2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol","Impurities":["uridine","adenine","guanosine","inosine"],"InChI":"InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7-,10-/m1/s1","InChIKey":"OIRDTQYFTABQOQ-KQYNXXCUSA-N","MeSH Pharmacological Classification":"Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)","Melting Point":"235.5 °C","MolecularFormula":"C\u003csub\u003e10\u003c/sub\u003eH\u003csub\u003e13\u003c/sub\u003eN\u003csub\u003e5\u003c/sub\u003eO\u003csub\u003e4\u003c/sub\u003e","MolecularWeight":"267.24 g/mol","Odor":"Odorless","Opticalactivity":"UNSPECIFIED","Pharmacodynamics":"Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy and also indicated for conversion of sinus rhythm of paroxysmal supraventricular tachycardia. Adenosine has a short duration of action as the half life is \u003c10 seconds, and a wide therapeutic window. Patients should be counselled regarding the risk of cardiovascular side effects, bronchoconstriction, seizures, and hypersensitivity.","Physical Description":"Solid","PrevSalts":[],"PubChemId":60961,"Record Description":["Adenosine is a ribonucleoside composed of a molecule of adenine attached to a ribofuranose moiety via a beta-N(9)-glycosidic bond. It has a role as an anti-arrhythmia drug, a vasodilator agent, an analgesic, a human metabolite and a fundamental metabolite. It is a purines D-ribonucleoside and a member of adenosines. It is functionally related to an adenine.","The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole] and [regadenson]. Adenosine is also indicated in the treatment of supraventricular tachycardia.  Adenosine was granted FDA approval on 30 October 1989.","Adenosine is a metabolite found in or produced by Escherichia coli (strain K12, MG1655).","Adenosine is an Adenosine Receptor Agonist. The mechanism of action of adenosine is as an Adenosine Receptor Agonist.","Adenosine has been reported in Acanthus ilicifolius, Acanthus ebracteatus, and other organisms with data available.","Adenosine is a ribonucleoside comprised of adenine bound to ribose, with vasodilatory, antiarrhythmic and analgesic activities. Phosphorylated forms of adenosine play roles in cellular energy transfer, signal transduction and the synthesis of RNA.","ADENOSINE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 3 approved and 18 investigational indications.","Adenosine is a nucleoside that is composed of adenine and d-ribose. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. For instance, adenosine plays an important role in energy transfer - as adenosine triphosphate (ATP) and adenosine diphosphate (ADP). It also plays a role in signal transduction as cyclic adenosine monophosphate, cAMP. Adenosine itself is both a neurotransmitter and potent vasodilator. When administered intravenously, adenosine causes transient heart block in the AV node. Because of the effects of adenosine on AV node-dependent supraventricular tachycardia, adenosine is considered a class V antiarrhythmic agent.","Adenosine is a metabolite found in or produced by Saccharomyces cerevisiae.","A nucleoside that is composed of adenine and d-ribose. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter.","See also: Adenosine; Glycerin (component of); Adenosine; levomenol (component of); Adenosine; Niacinamide (component of) ... View More ...","Adenosine is a ribonucleoside composed of a molecule of adenine attached to a ribofuranose moiety via a beta-N(9)-glycosidic bond. It has a role as an anti-arrhythmia drug, a vasodilator agent, an analgesic, a human metabolite and a fundamental metabolite. It is a purines D-ribonucleoside and a member of adenosines. It is functionally related to an adenine."],"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Adenosine","Name":"Adenosine","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q190012","Name":"Adenosine","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00640","Name":"Adenosine","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/60961","Name":"Adenosine","Sub":false}]},{"Name":"ChemSpider","Urls":[{"Link":"https://www.chemspider.com/Chemical-Structure.61715227.html","Name":"Adenosine","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL477","Name":"Adenosine","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:16335","Name":"Adenosine","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=58-61-7","Name":"Adenosine","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0000050","Name":"Adenosine","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C00212","Name":"Adenosine","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/K72T3FS567","Name":"Adenosine","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID1022558","Name":"Adenosine","Sub":false}]}],"SMILES":"C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N","Solubility":"\u003e40.1 [ug/mL] (The mean of the results at pH 7.4)","StoreUNII":["K72T3FS567"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="106.707mm" version="1.2" viewBox="0 0 82.868 106.707" width="82.868mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#FF0D0D" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="107.0" stroke="none" width="83.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <g class="bond" id="mol1bnd1">
                        
                <line x1="2.907" x2="2.602" y1="63.989" y2="75.594"/>
                        
                <line x1="5.308" x2="5.04" y1="65.445" y2="75.658"/>
                      
                <line class="hi" stroke="#3050F8" x1="2.602" x2="2.7545" y1="75.594" y2="69.7915"/>
                <line class="hi" stroke="#3050F8" x1="5.04" x2="5.1739999999999995" y1="75.658" y2="70.5515"/>
            </g>
                  
            <line class="bond" id="mol1bnd2" x1="5.644" x2="15.108" y1="81.319" y2="86.967"/>
                  
            <g class="bond" id="mol1bnd3">
                        
                <line x1="15.108" x2="28.732" y1="86.967" y2="80.155"/>
                        
                <line x1="15.211" x2="26.294" y1="84.189" y2="78.648"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd4" x1="28.732" x2="28.732" y1="80.155" y2="64.599"/>
                  
            <g class="bond" id="mol1bnd5">
                        
                <line x1="28.732" x2="18.863" y1="64.599" y2="58.739"/>
                        
                <line x1="26.294" x2="17.618" y1="65.987" y2="60.836"/>
                      
                <line class="hi" stroke="#3050F8" x1="18.863" x2="23.7975" y1="58.739" y2="61.669"/>
                <line class="hi" stroke="#3050F8" x1="17.618" x2="21.956" y1="60.836" y2="63.4115"/>
            </g>
                  
            <line class="bond" id="mol1bnd6" x1="2.907" x2="12.553" y1="63.989" y2="58.63"/>
                  
            <line class="bond" id="mol1bnd7" x1="28.732" x2="40.487" y1="64.599" y2="61.422"/>
                  
            <line class="bond" id="mol1bnd8" x1="46.287" x2="52.422" y1="64.131" y2="72.936"/>
                  
            <g class="bond" id="mol1bnd9">
                        
                <line x1="45.893" x2="52.422" y1="81.473" y2="72.936"/>
                        
                <line x1="43.957" x2="49.403" y1="79.992" y2="72.869"/>
                      
                <line class="hi" stroke="#3050F8" x1="45.893" x2="49.1575" y1="81.473" y2="77.2045"/>
                <line class="hi" stroke="#3050F8" x1="43.957" x2="46.68" y1="79.992" y2="76.4305"/>
            </g>
                  
            <line class="bond" id="mol1bnd10" x1="28.732" x2="39.902" y1="80.155" y2="83.931"/>
                  
            <path class="bond" d="M49.326 46.321l-.658 -.239l-5.059 10.124l1.542 .561l1.541 .561z" fill="#000000" id="mol1bnd11" stroke="none"/>
                  
            <line class="bond" id="mol1bnd12" x1="48.997" x2="40.503" y1="46.202" y2="33.625"/>
                  
            <line class="bond" id="mol1bnd13" x1="40.503" x2="49.896" y1="33.625" y2="21.61"/>
                  
            <line class="bond" id="mol1bnd14" x1="49.896" x2="64.151" y1="21.61" y2="26.817"/>
                  
            <line class="bond" id="mol1bnd15" x1="64.151" x2="63.759" y1="26.817" y2="38.099"/>
                  
            <line class="bond" id="mol1bnd16" x1="48.997" x2="60.017" y1="46.202" y2="43.051"/>
                  
            <path class="bond" d="M63.955 26.527l.391 .581l12.945 -6.769l-.157 -2.269l-.18 -2.592z" fill="#000000" id="mol1bnd17" stroke="none"/>
                  
            <line class="bond" id="mol1bnd18" x1="76.799" x2="76.014" y1="18.295" y2="6.999"/>
                  
            <g class="bond" id="mol1bnd19">
                        
                <line stroke="#000000" x1="49.56" x2="50.233" y1="21.706" y2="21.514"/>
                        
                <line stroke="#FF0D0D" x1="48.72" x2="49.874" y1="19.68" y2="19.35"/>
                        
                <line stroke="#FF0D0D" x1="47.881" x2="49.515" y1="17.654" y2="17.187"/>
                        
                <line stroke="#FF0D0D" x1="47.041" x2="49.157" y1="15.628" y2="15.023"/>
                        
                <line stroke="#FF0D0D" x1="46.202" x2="48.798" y1="13.602" y2="12.86"/>
                        
                <line stroke="#FF0D0D" x1="45.363" x2="48.44" y1="11.576" y2="10.696"/>
                      
            </g>
                  
            <g class="bond" id="mol1bnd20">
                        
                <line stroke="#000000" x1="40.491" x2="40.515" y1="33.975" y2="33.275"/>
                        
                <line stroke="#FF0D0D" x1="38.305" x2="38.347" y1="34.149" y2="32.95"/>
                        
                <line stroke="#FF0D0D" x1="36.119" x2="36.178" y1="34.323" y2="32.624"/>
                        
                <line stroke="#FF0D0D" x1="33.933" x2="34.009" y1="34.497" y2="32.298"/>
                        
                <line stroke="#FF0D0D" x1="31.747" x2="31.841" y1="34.672" y2="31.973"/>
                        
                <line stroke="#FF0D0D" x1="29.561" x2="29.672" y1="34.846" y2="31.647"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd21" x1="15.108" x2="14.684" y1="86.967" y2="98.358"/>
                  
            <path class="atom" d="M4.441 81.893h-.72l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .358 .024 .733v2.738h-.566v-4.899h.714l2.608 4.054h.03q-.006 -.107 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" fill="#3050F8" id="mol1atm2" stroke="none"/>
                  
            <path class="atom" d="M17.659 59.322h-.72l-2.62 -4.066h-.03q.012 .238 .03 .595q.024 .357 .024 .732v2.739h-.566v-4.9h.715l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.769h.578v4.9z" fill="#3050F8" id="mol1atm6" stroke="none"/>
                  
            <path class="atom" d="M45.72 62.982h-.72l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .357 .024 .733v2.738h-.566v-4.899h.714l2.608 4.054h.03q-.006 -.108 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" fill="#3050F8" id="mol1atm7" stroke="none"/>
                  
            <path class="atom" d="M45.11 87.485h-.72l-2.619 -4.066h-.03q.012 .238 .03 .595q.023 .358 .023 .733v2.738h-.565v-4.899h.714l2.608 4.054h.03q-.006 -.107 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" fill="#3050F8" id="mol1atm9" stroke="none"/>
                  
            <path class="atom" d="M65.882 42.017q.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q-.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM62.018 42.017q.0 .923 .387 1.458q.393 .53 1.221 .53q.839 .0 1.22 -.53q.387 -.535 .387 -1.458q.0 -.929 -.387 -1.453q-.381 -.523 -1.208 -.523q-.834 -.0 -1.227 .523q-.393 .524 -.393 1.453z" id="mol1atm14" stroke="none"/>
                  
            <g class="atom" id="mol1atm16">
                        
                <path d="M78.002 3.078q-.0 .756 -.256 1.328q-.256 .565 -.757 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.501 .309 .757 .875q.256 .565 .256 1.327zM74.138 3.078q-.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.459q-.0 -.929 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .523 -.393 1.452z" stroke="none"/>
                        
                <path d="M82.308 5.531h-.619v-2.286h-2.513v2.286h-.613v-4.9h.613v2.072h2.513v-2.072h.619v4.9z" stroke="none"/>
                      
            </g>
                  
            <g class="atom" id="mol1atm17">
                        
                <path d="M47.962 6.944q.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 .0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q-.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM44.099 6.944q-.0 .923 .387 1.458q.393 .53 1.22 .53q.84 .0 1.221 -.53q.386 -.535 .386 -1.458q.0 -.929 -.386 -1.453q-.381 -.524 -1.209 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" stroke="none"/>
                        
                <path d="M42.882 9.397h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619v4.9z" stroke="none"/>
                      
            </g>
                  
            <g class="atom" id="mol1atm18">
                        
                <path d="M27.521 33.092q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.757 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.251 -.566 .757 -.882q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .876q.256 .565 .256 1.327zM23.657 33.092q.0 .923 .387 1.459q.393 .529 1.221 .529q.839 .0 1.22 -.529q.387 -.536 .387 -1.459q-.0 -.929 -.387 -1.452q-.381 -.524 -1.208 -.524q-.834 -.0 -1.227 .524q-.393 .523 -.393 1.452z" stroke="none"/>
                        
                <path d="M22.441 35.545h-.619v-2.286h-2.513v2.286h-.613v-4.9h.613v2.072h2.513v-2.072h.619v4.9z" stroke="none"/>
                      
            </g>
                  
            <g class="atom" id="mol1atm19">
                        
                <path d="M16.482 104.657h-.721l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .358 .024 .733v2.738h-.566v-4.899h.715l2.607 4.054h.03q-.006 -.107 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" fill="#3050F8" stroke="none"/>
                        
                <path d="M20.788 104.657h-.619v-2.286h-2.513v2.286h-.613v-4.899h.613v2.071h2.513v-2.071h.619v4.899z" fill="#3050F8" stroke="none"/>
                        
                <path d="M23.293 106.147h-1.943v-.3l.771 -.779q.221 -.222 .372 -.393q.153 -.175 .232 -.339q.078 -.168 .078 -.365q.0 -.243 -.146 -.368q-.143 -.128 -.372 -.128q-.214 -.0 -.378 .075q-.161 .075 -.329 .207l-.193 -.243q.172 -.146 .393 -.246q.225 -.1 .507 -.1q.411 -.0 .65 .207q.24 .207 .24 .575q-.0 .228 -.097 .432q-.093 .2 -.264 .397q-.168 .196 -.393 .417l-.614 .604v.018h1.486v.329z" fill="#3050F8" stroke="none"/>
                      
            </g>
                
            <line class="hi" id="mol1bnd2" stroke="#3050F8" x1="5.644" x2="10.376000000000001" y1="81.319" y2="84.143"/>
            <line class="hi" id="mol1bnd6" stroke="#3050F8" x1="12.553" x2="7.73" y1="58.63" y2="61.3095"/>
            <line class="hi" id="mol1bnd7" stroke="#3050F8" x1="40.487" x2="34.6095" y1="61.422" y2="63.0105"/>
            <line class="hi" id="mol1bnd8" stroke="#3050F8" x1="46.287" x2="49.3545" y1="64.131" y2="68.5335"/>
            <line class="hi" id="mol1bnd10" stroke="#3050F8" x1="39.902" x2="34.317" y1="83.931" y2="82.043"/>
            <line class="hi" id="mol1bnd15" stroke="#FF0D0D" x1="63.759" x2="63.955" y1="38.099" y2="32.458"/>
            <line class="hi" id="mol1bnd16" stroke="#FF0D0D" x1="60.017" x2="54.507000000000005" y1="43.051" y2="44.6265"/>
            <line class="hi" id="mol1bnd18" stroke="#FF0D0D" x1="76.014" x2="76.4065" y1="6.998999999999999" y2="12.647"/>
            <line class="hi" id="mol1bnd18" stroke="#FF0D0D" x1="76.014" x2="76.4065" y1="6.998999999999999" y2="12.647"/>
            <line class="hi" id="mol1bnd21" stroke="#3050F8" x1="14.684" x2="14.896" y1="98.358" y2="92.6625"/>
        </g>
          
    </g>
    
</svg>
","Taste":"Mild, saline, or bitter taste","Therapeutic Uses":"Analgesics; Anti-Arrhythmia Agents; Vasodilator Agents","Title":"Adenosine","UNII":"K72T3FS567","Wikidata":"Q190012","XLogP":-1.1,"pH":"pH = 4.5-7.5 (solution of 3 mg/mL adenosine and 9 mg/mL sodium chloride in water)"}